The lungs can substantially influence the redox status of redox-active plasma constituents. Our objective was to examine aspects of the kinetics and mechanisms that determine pulmonary disposition of redoxactive compounds during passage through the pulmonary circulation. Experiments were carried out on rat and mouse lungs with 2,3,5,6-tetramethyl-1,4-benzoquinone [duroquinone (DQ)] as a model amphipathic quinone reductase substrate. We measured DQ and durohydroquinone (DQH2) concentrations in the lung venous effluent after injecting, or while infusing, DQ or DQH2 into the pulmonary arterial inflow. The maximum net rates of DQ reduction to DQH2 in the rat and mouse lungs were ϳ4.9 and 2.5 mol ⅐ min Ϫ1 ⅐ g dry lung wt Ϫ1 , respectively. The net rate was apparently the result of freely permeating access of DQ and DQH2 to tissue sites of redox reactions, dominated by dicumarol-sensitive DQ reduction to DQH2 and cyanide-sensitive DQH2 reoxidation back to DQ. The dicumarol sensitivity along with immunodetectable expression of NAD(P)H-quinone oxidoreductase 1 (NQO1) in the rat lung tissue suggest cytoplasmic NQO1 as the dominant site of DQ reduction. The effect of cyanide on DQH2 oxidation suggests that the dominant site of oxidation is complex III of the mitochondrial electron transport chain. If one envisions DQ as a model compound for examining the disposition of amphipathic NQO1 substrates in the lungs, the results are consistent with a role for lung NQO1 in determining the redox status of such compounds in the circulation. For DQ, the effect is conversion of a redox-cycling, oxygen-activating quinone into a stable hydroquinone. lung oxygen consumption; indicator dilution; reaction kinetics; mathematical modeling; NAD(P)H-quinone oxidoreductase; mitochondrial electron transport THE LUNGS (2, 3, 8, 12) and particularly the pulmonary endothelium (9, 13, 37-39, 41) can alter the redox status of certain redox-active compounds as they pass through the pulmonary circulation. This has the potential for affecting the systemic arterial concentrations of these compounds, as well as their pro-or antioxidant status and propensity for other reactions, with implications for the systemic, as well as pulmonary, effects of such substances. Quinones comprise a class of redoxactive compounds having a wide range of physical and chemical properties, and there are a number of mammalian enzymes that have quinone reductase activity (15). Therefore, compounds can be chosen from this class for properties that are particularly useful for probing processes by which the lungs can affect the redox status of blood-borne redox-active compounds. We carried out the present study to determine the effect of passage through the pulmonary circulation on the redox status of 2,3,5,6-tetramethyl-1,4-benzoquinone (duroquinone, subsequently referred to as DQ), infused or injected into the pulmonary artery of intact lungs from rats and mice, and to examine some aspects of the kinetics and mechanisms that determine the net influence of passage through the lungs on the redox status of DQ exiting via the pulmonary venous effluent. DQ was chosen as the model quinone for this study because it is an amphipathic, nonarylating quinone that has been used extensively in studies of quinone redox metabolism and mitochondrial electron transport in isolated cell and subcellular systems in the past (14, 16, 22, 27, 30, 36, 50, 55) , thus providing direction for studies of the processes involved in DQ disposition in the intact organ.
THE LUNGS (2, 3, 8, 12) and particularly the pulmonary endothelium (9, 13, (37) (38) (39) 41) can alter the redox status of certain redox-active compounds as they pass through the pulmonary circulation. This has the potential for affecting the systemic arterial concentrations of these compounds, as well as their pro-or antioxidant status and propensity for other reactions, with implications for the systemic, as well as pulmonary, effects of such substances. Quinones comprise a class of redoxactive compounds having a wide range of physical and chemical properties, and there are a number of mammalian enzymes that have quinone reductase activity (15) . Therefore, compounds can be chosen from this class for properties that are particularly useful for probing processes by which the lungs can affect the redox status of blood-borne redox-active compounds. We carried out the present study to determine the effect of passage through the pulmonary circulation on the redox status of 2,3,5,6-tetramethyl-1,4-benzoquinone (duroquinone, subsequently referred to as DQ), infused or injected into the pulmonary artery of intact lungs from rats and mice, and to examine some aspects of the kinetics and mechanisms that determine the net influence of passage through the lungs on the redox status of DQ exiting via the pulmonary venous effluent. DQ was chosen as the model quinone for this study because it is an amphipathic, nonarylating quinone that has been used extensively in studies of quinone redox metabolism and mitochondrial electron transport in isolated cell and subcellular systems in the past (14, 16, 22, 27, 30, 36, 50, 55) , thus providing direction for studies of the processes involved in DQ disposition in the intact organ.
The results reveal the high capacity of the lungs for reducing DQ to durohydroquinone (DQH 2 ), provide insight into the overall disposition of DQ that determines its redox status in the venous effluent on passage through the lungs, and demonstrate some issues involved in probing plasma-borne substrate redox metabolism in the intact organ.
METHODS
Materials. DQ and other chemicals not otherwise specified were purchased from Sigma (St. Louis, MO). The DQH 2 was generated from DQ with potassium borohydride as described in Ref. 18 . For lung studies, except when oxygen consumption was measured, the perfusate was a salt solution containing (in mM) 4.7 KCl, 2.51 CaCl 2, 1.19 MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO 3, and 5.5 glucose, with either 5% bovine serum albumin (BSA) or 2.5% Ficoll (average molecular mass 70 kDa). When lung oxygen consumption was measured, the perfusate was Hanks' balanced salt solution with 10 mM HEPES buffer (pH 7.4), 5.5 mM glucose, and 5% BSA added (referred to as HBSS/HEPES). When the perfusate contained BSA, the sample collection tubes were prepared by adding EDTA to obtain a final sample concentration of 1.5 mM after sample collection.
Lung experiments. Experiments, approved by the Institutional Animal Care and Use Committee of the Veterans Affairs Medical Center, Marquette University, were carried out using lungs from Sprague Dawley rats (Charles River) or CD-1 mice (Charles River). The lung preparation has been described previously for the rat lung (2) and was similar but scaled in size for the mouse lung. Each rat or mouse was anesthetized (pentobarbital sodium, 0.04 mg/g body wt ip). The trachea was clamped, and the chest was opened. Heparin (0.7 IU/g body wt) was injected into the right ventricle. The pulmonary artery and trachea were cannulated, and for the rat, the left atrium was also cannulated via the left ventricle. The cannulas were made of polyethylene tubing [1.67 mm inner diameter (ID), 2.42 mm outer diameter (OD) for the rat; and 0.86 mm ID, 1.27 mm OD for the mouse]. For the mouse, the heart was cut away allowing the venous effluent to drain directly from the severed pulmonary vein. The lungs were removed from the chest and attached to a ventilation and perfusion system. The single-pass perfusion system was primed with the perfusate maintained at 37°C and equilibrated with a gas mixture of 15% O 2 and 6% CO2 in N2 resulting in perfusate PO2, PCO2, and pH of ϳ105 Torr, 40 Torr, and 7.4, respectively. An initial volume of perfusate (ϳ40 ml for the rat and 4 ml for the mouse) was pumped (Master Flex roller pump) through the lungs until the lungs and venous effluent were visually clear of blood. The flow rate was then set at 10 ml/min for the rat lungs and 2 ml/min for the mouse lungs. The lungs were ventilated with an 8 mmHg end-inspiratory and a 3 mmHg end-expiratory pressure at 40 breaths per min for the rat and 80 per min for the mouse and with the same gas composition as used to gas the perfusate. The pulmonary arterial pressure, which was referenced to atmospheric pressure at the level of the left atrium, was monitored continuously during the course of the experiments. For both rat and mouse lungs, the venous effluent pressure was atmospheric pressure. At the end of each experiment, the lungs were weighed dried and reweighed.
To measure the fate of DQ on passage through the lungs, the experiments were either pulse infusion (both rat and mouse lungs) or bolus injection (rat lungs only). For the pulse infusion experiments, the reservoir feeding the perfusion pump was emptied and refilled with perfusate of the composition indicated above and referred to as "control perfusate" or with perfusate of otherwise the same composition but containing one or more of the metabolic inhibiters indicated below, referred to as "experimental perfusate." After 4-20 min of perfusion with the control or experimental perfusate, the reservoir was refilled with the same perfusate except that DQ or DQH2 (concentrations dependent on the protocol as indicated in Sample analysis) was included. Samples of the venous effluent were then obtained at intervals during the subsequent 50-120 s of perfusion for the rat lung or 70-150 s of perfusion for the mouse lung. In some pulse experiments, the sampling was continuous, and an additional pulse infusion was carried out with the perfusate containing 4.6 M fluorescein isothiocyanate dextran (FITC-dex, average molecular wt ϳ43,200), but without DQ or DQH2. The FITC-dex was used as a vascular reference indicator to measure the time course for DQ or DQH 2 appearance in the venous effluent had DQ or DQH 2 been simply convected through the pulmonary vessels with the perfusate without interacting with the lung.
For the bolus injection experiments, an injection loop was included in the arterial line to allow introduction of a 0.1-ml bolus into the arterial inflow without altering the flow or perfusion pressure. At the same time that the bolus was introduced into the arterial inflow, the venous outflow was diverted into a sample collector for continuous collection of the lung effluent at a rate and duration depending on the perfusate flow rate. As in the pulse infusion experiments, the reservoir was filled with the desired perfusate, which was recirculated for 15-25 min, after which the reservoir was refilled with fresh experimental perfusate just before the bolus injection. The flow rate was then either left at 10 ml/min or increased to 30 ml/min, and the ventilation was halted. The bolus having the same composition as the perfusate, but with either 0. 4 For the bolus or for the continuous sampling pulse, at the end of each experiment, the lungs were removed from the perfusion system, and an additional FITC-dex bolus or pulse, respectively, was carried out but with the lungs removed and the arterial and venous cannulas connected directly together for rat lungs or with just the arterial cannula for mouse lungs. The data from these "tubing only" experiments were used to obtain the system transit time for calculation of the lung vascular mean transit time and volume. For each kind of experiment, the same procedure was carried out at least once with DQ or DQH2 bolus or pulse in the tubing only experiment to assess any possible binding of the substrates to the tubing.
Sample analysis. When the perfusate contained BSA, each venous effluent sample from either the pulse or bolus experiments was first centrifuged for 1 min at 5,600 g (model 10MVSS microcentrifuge; Costar, Cambridge, MA). Then, 50-100 l of each sample were added to each of two microcentrifuge tubes, one prefilled with 10 l of potassium ferricyanide (1.8-7.2 mM) to oxidize any DQH2 to DQ, and the other prefilled with 10 l of deionized water. Ice-cold absolute ethanol (0.4-0.8 ml) was then added, and the samples were mixed and centrifuged at 5,600 g for 5 min at 10°C. One hundred microliters of the resulting supernatant were added to a spectrophotometric quartz microcell, and absorbance at 265 nm was recorded using a Beckman DU 7400 spectrophotometer (Beckman Instruments, Fullerton, CA). When the perfusate contained Ficoll instead of BSA, DQH2 was oxidized by adding hydrogen peroxide (H2O2, 0.1 mM) and peroxidase (7.4 units, Sigma P-8125) to the microcentrifuge tubes, and the absorbance was recorded as above without the addition of ethanol.
Sample concentrations (in M) of DQ, [DQ] , and DQH2, [DQH2] were calculated from the absorbances of the fully oxidized (following the addition of potassium ferricyanide or peroxidase/H2O2, Abs1) and the original unoxidized (Abs2) venous samples and from the micromolar extinction coefficients at 265 nm of DQ, 0.02164 M Ϫ1 cm Ϫ1 , and DQH2, 0.0017 M Ϫ1 cm Ϫ1 , as follows A perfusate sample that had passed through the lungs but contained no DQ or DQH 2 was treated in the same manner as the rest of the samples and used as the blank for absorbance measurements. In addition, for the bolus experiments, measured volumes of the bolus solution were added to samples that emerged in the venous effluent before the appearance of the bolus contents. These samples were used as standards for determining the fraction of bolus contents per milliliters of venous effluent sample. For the pulse infusion protocol, the lung effluent concentration was compared with the perfusion system effluent concentration measured with the lungs removed from the perfusion system.
Lung oxygen consumption. To measure the rat lung oxygen consumption, we prepared the lungs as indicated above except that, after the rat was anesthetized, it was provided with 100% O 2 to breathe for 5 min. The trachea was then occluded before the chest was opened. This resulted in the absorption of all alveolar gas, so when the lungs were perfused, the source of oxygen was that dissolved in the perfusate. The lungs were again connected to the perfusion system supported by the tracheal, arterial, and venous cannulas, but they were not ventilated. The perfusion system was primed with the HBSS/HEPES perfusate and equilibrated with room air.
After the blood was washed from the lungs, the venous cannula was connected to the stirred reservoir, thereby forming a recirculating perfusion system containing a total of 30 ml of perfusate including the lung vascular volume. The PO 2 of the reservoir was monitored continuously on a YSI 5300 Biological Oxygen Monitor (YSI). To begin an oxygen consumption measurement, the perfusate PO 2 was raised to ϳ160 Torr (a little higher than atmospheric oxygen) by bubbling with oxygen. Then the decrease in reservoir PO 2 (PO2res) with time was monitored for ϳ10 min or until it had fallen to ϳ60 Torr, depending on which came first.
To calculate the lung oxygen consumption, the decrease in PO 2res, with time (t) as oxygen was consumed by the lungs was represented by
where k␣ (Torr/min) is the rate of change in PO2res(t) due to oxygen consumption by the lungs, and k␤ (min Ϫ1 ) is a diffusion coefficient-like term reflecting any exchange of oxygen between the perfusate and atmospheric PO 2 (PO2atm). The diffusion term was included because no attempt was made to prevent any small amount of oxygen diffusion through the pleural surface or to perfectly seal the reservoir. Equation 5 is the solution for Eq. 4 with PO 2res(t ϭ 0) ϭ PO2atm.
The parameters k ␣ and k␤ were obtained by fitting Eq. 5 to the PO 2res(t) data. The oxygen consumption (mol/min) of the lung was then k ␣ times the perfusate oxygen solubility times the recirculating perfusate volume. Lung experimental protocols. To determine the capacity of the rat and mouse lungs to effect conversion of pulmonary arterial DQ to pulmonary venous DQH 2, we used the pulse infusion method with the lungs perfused with control perfusate at 10 ml/min for rat lungs or 2 ml/min for mouse lungs. Four pulse infusions were performed with sequentially increasing reservoir (pulmonary arterial) DQ concentrations, and then a fifth infusion was a repeat of the low concentration infusion carried out to evaluate the effect of DQ infusion history and or time on the results.
To determine the influence of the metabolic inhibitors on the redox status of DQ in the venous effluent from rat and mouse lungs, we carried out the pulse infusions using the control perfusate and then repeated it with experimental perfusate containing cyanide (2 mM) alone, rotenone (10-20 M), followed by rotenone plus cyanide, dicumarol alone (20 M with BSA perfusate, 5 M with Ficoll perfusate), followed by dicumarol plus cyanide.
The DQ bolus experiments in rat lungs were carried out to evaluate the accessibility of DQ and DQH 2 to their respective tissue volumes of distribution. For DQ, this required first inhibiting DQ reduction, which was accomplished by perfusing the lung with perfusate wherein glucose was replaced by 10 mM 2-deoxyglucose (2-DG), and the flavoprotein inhibitor diphenyleneiodonium (DPI, 10 M) was added 15 min before the DQ bolus injection. The [ H]alfentanil bolus experiments were carried out to determine the rat lung capillary volume and transit time distribution as described in (7) .
The oxygen consumption was measured with control perfusate, and the lungs were divided into two groups. In one group, rotenone [17.7 Ϯ 2.9 (SD) M] and thenoyltrifluoroacetone (TTFA, 17.7 Ϯ 2.9 M) were then added to the perfusate, and the oxygen consumption was measured again. Then with the rotenone and TTFA still present, DQ (0.177 Ϯ 0.029 mM) was added. Finally, with rotenone, TTFA, and DQ still present, cyanide (1.77 Ϯ 0.29 mM) was added. In the other group, cyanide alone was added to the perfusate after the control measurement.
Statistical comparisons of effluent [DQ], [DQH2], or oxygen consumption between control and experimental conditions was by ANOVA, followed by Tukey's test with P Ͻ 0.05 as the criterion for statistical significance.
Additional measurements. The DQ (250-1,000 M) and DQH2 (125-250 M) binding to 5% BSA or DQ (50 M) and DQH2 (50 M) binding to 2.5% Ficoll in the perfusate was determined using the Amicon ultrafiltration system as previously described (7, 8) . At 5% BSA, 95.6 Ϯ 0.5 (SE) % of the DQ and 76 Ϯ 1.0% of the DQH2 were BSA bound, and the bound fractions were independent of DQ and DQH2 concentrations within the concentration range studied. At 2.5% Ficoll, 63% of the DQ and 60% of the DQH2 were associated with Ficoll. For the model interpretation of the DQ disposition in the lungs described below (see KINETIC MODEL), these fractions are converted to ␣1 and ␣3, defined by ␣1 ϭ 1 ϩ (DQ bound fraction/DQ free fraction) and ␣3 ϭ 1 ϩ (DQH2 bound fraction/DQH2 free fraction), respectively. Thus the values of ␣1 and ␣3 were set at 25 and 4.2, respectively, for model simulations of experiments carried out with the 5% BSA perfusate and at 2.7 and 2.5, respectively, for the 2.5% Ficoll perfusate.
DQH2 auto-oxidation was evaluated by monitoring the [DQ] in lung effluent samples (with and without EDTA added to the BSA perfusate) for 50 min following collection. In EDTA-free BSA perfusate effluent samples, the auto-oxidation rate of DQH 2 was Ͻ1.1%/min and undetectable on that time frame in Ficoll perfusate or BSA perfusate with EDTA added.
To confirm the presence of NAD(P)H-quinone oxidoreductase 1 (NQO1) in the rat lungs, we carried out immunoblot analysis as follows. After perfusion, the lungs were weighed, minced, and homogenized in 5 ml buffer/g tissue [buffer composition (in mM): 10 N-2-hydroxyethylpiperzaine-NЈ-2-ethanesulfonic acid, 250 sucrose, 3 EDTA, 1 phenylmethylsulfonyl fluoride, and 1% protease inhibitor cocktail (Sigma, catalog no. P8340)] at 4°C using a Polytron homogenizer. The homogenate was centrifuged for 65 min at 145,000 g. A portion of the resulting supernatant (41 g of protein) and purified recombinant human NQO1 protein (0.25 ng) (47) were subjected to electrophoresis using Invitrogen's (Carlsbad, CA) NuPAGE LDS sample buffer, 4-12% gradient Nu-PAGE Bis-Tris gel, and MES-SDS running buffer. The proteins were transferred to a nitrocellulose membrane, which was incubated for 1 h in Tris-buffered saline containing 0.1% Tween 20 and 2% BSA, the latter as a blocking agent. The membrane was then incubated sequentially in a 1:10 dilution of tissue culture supernatant containing anti-NQO1 monoclonal antibodies (IgG 1) from two mouse hybridoma cell lines (A180 and B771, mixed 1:1) (47), a 1:7,500 dilution of goat ␣-mouse IgG-horseradish peroxidase (Jackson ImmunoResearch Laboratories), and the Supersignal West Pico Chemiluminescent substrate (Pierce). The signal was captured on CL-Xposure Film (Pierce). As a control, nonspecific mouse IgG 1 was substituted for the ␣-NQO1 monoclonal antibodies. Table 1 provides some general information on the lungs and animals studied. In addition, the perfusion pressures at the beginning and end of the experiments were for rats (10 ml/min flow rate) 6.3 Ϯ 0.3 and 6.7 Ϯ 0.4 mmHg, respectively, and for mice (2 ml/min) 6.4 Ϯ 0.2 and 6.8 Ϯ 0.3 mmHg, respectively, and were not significantly different among lungs perfused with the different experimental perfusates. For the rat lungs perfused at 30 ml/min, the pressure averaged 8.9 Ϯ 0.7 mmHg. The wet/dry lung ratios were not significantly different in the lungs perfused only with control perfusate vs. lungs perfused with control and experimental perfusate(s) (5.7 Ϯ 0.1 vs. 5.6 Ϯ 0.1, respectively, for rats; 5.5 Ϯ 0.1 vs. 5.6 Ϯ 0.1, respectively, for mice). Because lung injury is typically accompanied by increased vascular resistance and wet/dry weight, the comparisons between experimental and control conditions suggest that the inhibitors did not cause significant nonspecific injury to the lungs on the time frame of the experiments. H]alfentanil data from the rat. The value for the mouse lung Vc is assumed to be the same fraction of Vv as for the rat lung, and RDc and SKWc values for the mouse lung are assumed to be the same as the rat lung values, as in their application in the model. The lung weights are from all the lungs used in the entire study, n ϭ 29 and 26 for rat and mouse, respectively. The vascular volumes are for the subsets of experiments in which the relevant transient data were obtained, n ϭ 5 and 4 for rat and mouse lungs, respectively. The body weights for all the rats and mice used in the study were 323 Ϯ 6 and 30 Ϯ 1 g, respectively, and 313 Ϯ 8 and 28 Ϯ 3, respectively, for the subsets. Figure 2 is representative of DQ and DQH 2 infusions in the mouse lung. When DQ was infused into the mouse lung, a considerably smaller fraction emerged as DQH 2 than in the rat lung, and when DQH 2 was infused, its oxidation to DQ was also more evident than in the rat lung. As in the rat lung, a nearly steady state was achieved within the infusion period.
EXPERIMENTAL RESULTS
The capacity of rat and mouse lungs for DQ reduction was evaluated by varying the infused [DQ] . However, to assess the possibility of residual effects of previous infusions in these experiments, we repeated the low-concentration (ϳ45 M) pulse after the full concentration range had been covered. The low-concentration infusions produced DQH 2 fractions that were 0.88 Ϯ 0.03 SE at the beginning and 0.87 Ϯ 0.02 at the end of this protocol for the rat lungs and 0.36 Ϯ 0.02 and 0.32 Ϯ 0.01, respectively, for the mouse lungs. Having established that the multiple pulses and high DQ concentrations did not have significant cumulative or irreversible effects, we plotted the steady-state rate of DQH 2 output from rat and mouse lungs vs. the log mean concentration of the infused DQ (Fig. 3) (10) . The net rate vs. log mean concentration data have a hyperbolic appearance, with apparent maximum rates of DQH 2 output of 4.9 and 2.5 mol ⅐ min Ϫ1 ⅐ g dry lung wt
Ϫ1 for rat and mouse lungs, respectively, with a log mean perfusate [DQ] resulting in half the these maximum rates, being 32 M (free ϩ BSA bound DQ) and 83 M for rat and mouse lungs, respectively. On the basis of the fraction of DQ bound to BSA, these values are equivalent to 1.3 and 3.4 M free [DQ], respectively. Figure 4 summarizes the pulse infusion data obtained from rat lungs with the control perfusate or with the experimental perfusate containing rotenone, cyanide, or cyanide plus rotenone. When DQ was infused, most was reduced to DQH 2 , and when DQH 2 was infused, a small fraction was converted to DQ. Cyanide decreased the effluent DQ fraction during DQH 2 infusion. Rotenone treatment resulted in lower effluent DQH 2 fraction during DQ infusion and higher DQ fraction during DQH 2 infusion, both of which were reversed by the addition of cyanide. The Fig. 4 results suggest that the fraction of DQ converted to DQH 2 under the control conditions was the result of the combination of both DQ reduction and DQH 2 reoxidation. However, the net DQH 2 oxidation was small. To better evaluate the oxidation process, we carried out experiments on mouse lungs, which have a lower net reduction rate than rat lungs (e.g., Fig. 3 ). In the mouse lungs, the effluent DQH 2 fraction during DQ infusion was considerably smaller than in the rat lungs, and the DQ fraction during DQH 2 infusion was higher (Fig. 5) . Cyanide alone increased the effluent DQH 2 fraction during DQ infusion and decreased the DQ fraction during DQH 2 infusion. As in the rat lung, rotenone alone resulted in a lower DQH 2 fraction in the venous effluent during DQ infusion and higher DQ fraction during DQH 2 infusion, which, as in the rat lung, was reversed by cyanide.
An initial attempt was made to evaluate the effect of dicumarol in the rat lungs with the BSA-containing perfusate. Dicumarol (20 M) had little effect on the effluent DQH 2 fraction during the infusion of DQ (89.0 Ϯ 1.4 SE % vs. 84.4 Ϯ 2.1%, respectively) or the DQ fraction during the infusion of DQH 2 (9.5 Ϯ 0.6% vs. 10.0 Ϯ 0.8%, respectively). Given the high affinity of dicumarol for plasma albumin (11), we then examined the dicumarol effect with the BSA perfusate replaced by the Ficoll perfusate. Figure 6 is a summary of the effects of dicumarol in the absence of albumin, showing that dicumarol markedly inhibited DQH 2 output during DQ infusion. Interestingly, most of this dicumarol effect was reversible by cyanide.
The bolus experiments were carried out to provide data in which the transient information about DQ disposition on passage through the lungs is emphasized, thus providing insight into the tissue permeation of DQ and DQH 2 . Figure 7 presents the data obtained from bolus injections into the pulmonary artery of a rat lung with the flow rate set at 10 or 30 ml/min and without or with the reduction inhibited by including DPI (10 M) and 2-DG (10 mM) in the perfusate. The rationale behind the use of 2-DG and DPI to inhibit reduction in the lungs was that 2-DG would decrease production of electron donor NAD(P)H and that quinone reductases are generally flavoproteins inhibited by DPI. This inhibitor regimen was used rather than dicumarol for these experiments because removal of BSA from the perfusate, required for dicumarol inhibition, results in a large DQ tissue-to-perfusate partition coefficient. The resulting low effluent DQ and DQH 2 concentrations during the bolus transient are disadvantageous for the data analysis described in KINETIC MODEL. As in the pulse experiments, the FITCdex concentration vs. time curves indicate what the effluent DQ curve would have been had the DQ not interacted with the lung as it passed through the pulmonary vessels.
A dominant feature of the [DQH 2 ] curves in Fig. 7 , A and B, and the [DQ] curve in Fig. 7C is that they are shifted to the right and more dispersed than the FITCdex curves in a manner reminiscent of a flow-limited distribution into the tissue (7, 29) . By comparing the Fig. 8 results for the [DQ] ϩ [DQH 2 ] curves obtained for the two flow rates with the time scales adjusted to take into account the flow-dependent difference in vascular residence times, we see that the shift appears to be virtually independent of the flow rate, which is also indicative of a flow-limited tissue distribution. The total DQ ϩ DQH 2 recovered during the sampling period was Ͼ98% for both 10 and 30 ml/min flow rates, and with the control perfusate most of the DQ injected emerged as DQH 2 . When reduction was inhibited, the relative concentrations of DQ and DQH 2 were reversed, but otherwise the shapes of the curves were not much different. However, the total DQ ϩ DQH 2 recovered in the venous effluent was only 80%.
These bolus data suggest that, on the time scale of these experiments, there appears to be no significant barrier to the diffusion of DQ or DQH 2 into the tissue. As a formal test of this interpretation of the form of DQ ϩ DQH 2 curves, the delayed wave transformation developed by Goresky (29) Because the reduction was so nearly complete with the control perfusate, one possibility that might be considered is that DQ itself does not actually enter the cells, but instead the reduction occurs on the cell surface followed by cell permeation of the resulting DQH 2 . This possibility seems to be ruled out by the fact that the DQ ϩ DQH 2 retained its flow-limited character even when the reduction was nearly eliminated and the effluent was mainly DQ rather than DQH 2 (Fig.  7C) . When the reduction was inhibited, some of the DQ also remained in the lungs, and, therefore, the delayed wave transformation was not applicable. However, the flow-limited model was able to account for the data as indicated in the kinetic model results described in KINETIC MODEL. This, along with the fact that the quinones are generally less hydrophilic than their respective hydroquinones, is consistent with both forms having very rapidly equilibrating access to their respective tissue volumes of distribution.
The distribution of pulmonary capillary transit (Fig. 9A) , as previously described (5, 7) . This was necessary to account for the transit time Table 1 .
The oxygen consumption provides a measure of the overall rate at which reducing equivalents are being utilized by the lungs under the respective experimental conditions. In addition, the data in Fig. 10 demonstrate that the depression of oxygen consumption by complex I and/or II inhibitors was reversible by DQ and, furthermore, that this DQ effect was inhibited by cyanide.
The immunoblot shown in Fig. 11 confirms the presence of NQO1 in the rat lungs. The mouse ␣-human NQO1 monoclonal antibody does not bind sufficiently to the mouse enzyme to be useful for this evaluation in the mouse lung.
KINETIC MODEL
To aid interpretation of data obtained with bolus and pulse experiments, we expressed the hypothesized fate of DQ on passage through the lungs using the kinetic model presented in Ref. 8 with some modification for the specifics of DQ disposition (see APPENDIX). The model equations (Eqs. A1-A4), for a single capillary element consisting of a capillary volume and its surrounding tissue volume accessible to DQ and DQH 2 , become the basis for the whole organ model by taking into account the distribution of h c (t). During the transients produced by the bolus injection or the presteadystate phase of the pulse infusion, the identifiable model parameters include the reduction rate parameter (k red ) and the oxidation rate parameter (k o ), both with units of milliliters per second. To put these parameters in perspective, if one were to assume Michaelis-Menten reaction kinetics, they would be approximations to the V max /K m ratio for the overall DQ reduction and DQH 2 oxidation processes, respectively, that are contributing under a given set of experimental conditions. The other parameters are the DQ sequestration rate constant (k 7 , in M Ϫ1 ⅐ s Ϫ1 ); the number of DQ sequestration sites (Y 0 , in nmol), and the virtual volumes of distribution (V F1 and V F2 , in ml), which are measures of any rapidly equilibrating tissue interactions of DQ and DQH 2 , respectively.
The model fits to the data in Figs. 1, 2, and 7 are included to demonstrate the extent to which the model represented by Eqs. A1-A4 is capable of explaining the transient data over the range experimental conditions studied. The model fits were obtained using all the 10 . Rat lung oxygen consumption. Means Ϯ SE, n ϭ 6 for the control. For 3 of the lungs, the experimental sequence was the control measurement followed by rotenone ϩ thenoyltribluoroacetone (TTFA), rotenone ϩ TTFA ϩ DQ, and then rotenone ϩ TTFA ϩ DQ ϩ cyanide. For the other 3 lungs, the control measurement was followed by cyanide treatment alone. * Significantly lower than control. (Fig. 7) were estimated with k red allowed to change in the presence of 2-DG and DPI but assumed to be flow independent. The values were k red ϭ 291 ml ⅐ s Ϫ1 ⅐ g dry wt Ϫ1 , k o ϭ 2.4 ml ⅐ s Ϫ1 ⅐ g dry wt Ϫ1 , k 7 Y 0 ϭ 5.7 ml ⅐ s Ϫ1 ⅐ g dry wt Ϫ1 , V F1 ϭ 162 ml/g dry wt, and V F2 ϭ 20 ml/g dry wt. Treatment with 2-DG and DPI decreased k red to 13.8 ml ⅐ s Ϫ1 ⅐ g dry wt Ϫ1 . For the steady state during the pulse infusion, Eqs. A2-A4 in the APPENDIX reduce to WV c d͓DQ͔ dx
where 
͓DQ ͔͑x
where [DQ] 0 is the total (free ϩ protein bound) infused [DQ]
and
The capillary outlet (x ϭ L) steady-state [DQ] following the infusion of [DQH 2 ] is given by Eq. 9, which is the solution of Eq. 7 with the boundary conditions
where F is the total flow rate, [DQH 2 ] 0 is the infused [DQH 2 ], and
For a given h c (t) or relative flow distribution W(f), the venous effluent steady-state DQ concentrations following the infusion of DQ or DQH 2 are given by Eqs. 10 and 11, respectively
where Nx is the number of different transit times through the capillaries (t i ) or flow rates, F i ϭ F ⅐ f i , where f i ϭ t c /t i is the flow through all capillaries having the i-th transit time relative to the mean flow (6); W(f i ) and ⌬f i are the frequency of occurrence of f i and the relative flow increment, respectively, and are related to the h c (t) by W(f i ) ⅐ ⌬f i ⅐ f i ϭ h c (t i ) ⅐ ⌬t i , where ⌬t i is the capillary transit time increment.
Thus under steady-state conditions, the model parameters decrease to simply k red and k o , identifiable from the steady-state [DQ] following separate infusions of DQ and DQH 2 using Eqs. 10 and 11 in a Levenberg-Marquardt optimization routine (35) . The values are given in Figs. 12 and 13 for the various experimental conditions.
DISCUSSION
The results demonstrate the large capacity of the lungs, especially of the rat, to convert DQ to DQH 2 as DQ passes through the pulmonary circulation, and With regard to DQ and DQH 2 transport, the bolus data suggest that DQ and DQH 2 freely access their respective tissue volumes of distribution wherein the reactions occur. That is to say, at any time and location orthogonal to the axis of flow through the lung capillaries, the concentrations of DQ and DQH 2 at the reaction sites are essentially in equilibrium with their respective perfusate concentrations, without a significant intervening transport barrier. This conclusion, based on the delayed-wave, or flow-limited, behavior, does not in itself mean that reduction of DQ does not occur at the cell surface. In fact, endothelial cell (9) as well as other cell (1, 26, 31, 40, 48, 53) surfaces have quinone reductase activity. It simply means that the concentration at the reaction sites, wherever they are, is essentially in equilibrium with the perfusate concentration. This is consistent with the amphipathic nature of DQ, which has a fairly high water solubility (1.6 mM, Ref. 21) along with a high octanol/water partition coefficient (131, Ref. 42) .
A corollary to this conclusion is that the association of both DQ and DQH 2 with the plasma albumin (BSA) in the perfusate is rapidly equilibrating (4, 7). Any significant slowly dissociating albumin-bound fraction would have resulted in throughput that would have degraded the delayed wave transformation. Thus flowlimited access and rapidly equilibrating association with albumin are two of the model assumptions (hypotheses).
The h c (t), referred to as the "capillary transport function" (6, 7) , is another aspect of the DQ transport through the lungs included in the model. Because this information was not previously available for the rat lung, the method for its determination using the [ 14 C]diazepam and [
3 H]alfentanyl in the bolus injection experiment was applied (7) . Because the results indicate that h c (t), normalized with respect to lung size, for the normal rat lungs was similar to that previously obtained for the rabbit lung (7), application of that method to the smaller mouse lung was not considered to be worth the additional effort. It was assumed that h c (t) was similar enough in all the lungs in the study, including the mouse lungs, that after normalization to account for differences in lung sizes (vascular volumes) and flow rates, little error would be introduced by the assumption that they were the same.
Given these aspects of the DQ and DQH 2 transport on passage through the lungs, the model also includes representations of the dominant DQ reactions, namely, reduction of DQ, oxidation of DQH 2 , and sequestration of DQ. Figure 3 demonstrates that the capacity for converting DQ to DQH 2 was large. Despite the extensive literature on quinone biochemistry, particularly in fields such as toxicology, oncopharmacology, and mitochondrial electron transport (11, 14, 16-19, 22, 24-27, 30-34, 36, 40, 44-46, 49, 50-55) , there is a paucity of comparable studies on any intact organ, much less on the lungs. However, this capacity of the lungs may be appreciated by comparing the apparent maximum DQH 2 efflux rate (ϳ4.9 mol ⅐ min Ϫ1 ⅐ g dry lung wt Ϫ1 , Fig. 3 ) and the rate of oxygen consumption (ϳ2.4 mol ⅐ min Ϫ1 ⅐ g dry lung wt
Ϫ1
, Fig. 10 ) by the rat lungs, the latter (which needs to be multiplied by 2 for comparison with DQ reduction) being an approximation of the total steady-state consumption of reducing equivalents by the entire lung. The oxygen consumption of intact rat lungs has apparently not been reported before. The mean value observed in the present study (56 l ⅐ min Ϫ1 ⅐ g dry wt
) was slightly greater than previously reported for dog (48 l ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 ) or rabbit lungs (39 l ⅐ min Ϫ1 ⅐ g dry wt
) and within the range reported for slices of rat lungs (148-48 l ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 ) (23) . Figure 3 also establishes the concentration dependence of the net reaction, and the rest of the pulse infusion experiments in the study were carried out using inlet concentrations Ͻ50 M, which was considered to be advantageous for measurement, with only minor violation of the linear reaction approximations used in the model.
The sequestration of DQ is the model representation of any mechanism by which the DQ is prevented from returning to the perfusate as either DQ or DQH 2 within the time frame of the experiments. DQ is less water soluble than DQH 2 (21) , which may contribute to a greater propensity for nonspecific associations with other molecules, including the BSA in the perfusate, compared with DQH 2 . Any slowly dissociating interactions fall into the sequestration category and do not contribute to the effluent [DQ] and [DQH 2 ] after the transient phase has passed. Likewise, any rapidly dissociating associations within the tissue do not contribute during the steady state except insofar as they contribute to the tissue-perfusate partition coefficient, and they are not separable from the physical tissue volume of distribution.
The resulting model (APPENDIX) is similar to that developed in Ref. 8 , with one simplification being that because auto-oxidation of DQH 2 is virtually nil in the time frame of the experiments, auto-oxidation is not included in the model. The model applied to the bolus or the transient portions of the pulse data involves six free parameters representing the intrinsic rates of DQ reduction: k red , DQH 2 oxidation (k o ), DQ sequestration (k 7 ), Y 0 , and the virtual tissue volumes V F1 and V F2 accessible to DQ and DQH 2 , respectively. Although these parameters are independently identifiable from the data from a bolus injection, they are highly correlated, which undermines their robust estimation from the data from a single bolus or pulse infusion. Therefore, the full model (Eqs. A1-A4) was fit to data from multiple bolus (Fig. 7) or pulse infusions (Figs. 1 and 2 ) carried out under widely varying conditions (4). That is, for the data in Figs. 1, 2, and 7, the model was fit simultaneously to all the data shown.
Given the flow-limited distribution of DQ and DQH 2 , the model for the steady-state portions of the pulse infusions becomes considerably simplified, with k red and k o the only free parameters. However, they are not independently identifiable from a single pulse. At least two pulses are required, with either the flow rate, the albumin binding, or the ratio of infused DQ to DQH 2 varied between pulses to obtain parameter identifiability. Although the full model fit to the transient data is a best least-squares fit to an overdetermined data set, the steady-state model fit, with two parameters and two data points (the venous reduced or oxidized fraction from two pulses), is implicit but exact. The data in Figs. 4-6 , showing the effluent fractions of DQH 2 during the DQ infusion or the effluent fractions of DQ during the DQH 2 infusion, along with reduction and oxidation rate parameters (Figs. 12 and 13 ) from the steady-state model analysis, support several additional conclusions regarding DQ disposition on passage through the lungs.
The kinetic parameters obtained from the pulse infusion data are presented in Figs. 12 and 13 in a fashion analogous to the concentration data presented in Figs. 4-6 . This representation emphasizes the relationships between k red and k o needed to account for the effluent concentration data and the effectiveness of dicumarol inhibition on k red in the rat lungs. Comparison between the rate parameter (Figs. 12 and 13) and concentration (Figs. 4-6 ) data also helps to expose the impact that even a small k o compared with k red can have on net reduction. This is most obvious for the mouse lungs wherein a k o /k red of only ϳ0.36 can account for the greater net oxidation of infused DQH 2 than reduction of infused DQ. This is explainable largely by the different affinities of DQ and DQH 2 for BSA. The difference between rat and mouse lungs could be attributed entirely to the lower k red in the mouse lung (note the difference in scale between Figs.  12 and 13) . The k red s for the rat and mouse lungs were ϳ242 and 12 ml ⅐ min Ϫ1 ⅐ g dry wt
, respectively, whereas the respective k o s, were not distinguishable at ϳ4.1 and 3.9 ml ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 , respectively. The dicumarol effect points to NQO1 (42) , which Fig.  11 shows is present in the rat lungs, as the dominant reductase activity involved. For the species for which comparisons are available (rat, mouse, and human, Ref. 20) , rat NQO1 has the highest specific activity. However, it is not clear how that observation might factor into the explanation for the species differences in whole organ activity, wherein a number of other factors (e.g., the amount of enzyme) affecting overall activity may be operative.
In each experimental condition studied, the addition of cyanide decreased k o , consistent with a complex III oxidation site for DQH 2 . In other words, inhibition of mitochondrial complex IV by cyanide would be expected to promote reduction of complex III, thereby closing down complex III as a pathway for DQH 2 oxidation. Cyanide also tended to increase k red . This is most obvious in the mouse lungs with their relatively low reduction rate under the control conditions. Cyanide also reversed the effects of both rotenone and dicumarol on k red . The reversal might be related to the overall effect of cyanide on the redox poise of the cells. For example, cyanide has been observed to increase bovine pulmonary arterial endothelial cell NADH concentration severalfold (41) . Because dicumarol is a competitive inhibitor at the NAD(P)H binding site of NQO1 (43) , an increase in cellular NADH might diminish the inhibitory effect of dicumarol. In addition, or instead, the increase in electron donor concentration may increase the contribution of other reductases. It is notable that, with oxidation markedly suppressed by cyanide, the net reduction returned almost to the control level in the dicumarol inhibition experiments (Fig.  6 ). This can be explained by recovery of only a very small fractional of the control k red (Fig. 12 ) along with the relatively large DQ and DQH 2 tissue to perfusate partition coefficients resulting from the elimination of BSA from the perfusate. The latter was done to expose the dicumarol effect as indicated above.
The decrease in k red caused by rotenone might reflect a direct inhibition of the DQ reductase activity of complex I (54) . Complex I inhibition would also be expected to result in a more oxidized state of complex III, which might increase k o by promoting oxidation of DQH 2 via the hydroquinone oxidase-cytochrome c reductase activity of complex III (14, 30, 55) . This conjecture is supported by the oxygen consumption data shown in Fig. 10 , wherein the decrease in oxygen consumption in response to rotenone and TTFA was reversible by DQ (Fig. 10) . In other words, DQ reduction, presumably via NQO1, appears to have provided an electron transport bypass, allowing cytochrome c reduction to proceed and thus restoring oxygen consumption (14, 33) . Thus the effects of cyanide apparently indicate that the reoxidation of DQH 2 in the lung is predominantly via complex III. This is consistent with the concept that reduction by NQO1 followed by oxidation via complex III, thereby forming an electron bypass around complex I, may be a means by which low-molecular-weight amphipathic quinones reverse the effects of complex I deficiency diseases on mitochondrial ATP production (19, 51, 52) .
DQ is commonly thought of as a redox-cycling, oxygen-activating quinone via its one electron reduction by various mammalian enzyme systems, which have been studied most extensively in hepatocytes, liver mitochondria, and microsomes (16, 24, 27, 32, 46) . This was not directly addressed in the present study. However, the apparent predominance of reduction via NQO1, which is a two-electron reduction (17, 34) and the fact that cyanide largely inhibited the oxygen consumption-stimulating effect of DQ suggest that semiquinone formation is not a dominant reduction product in the lung, and the balance of enzyme activities contributing to the extracellular disposition of DQ on passage through the lungs is two-electron reduction. This would not necessarily be true for quinones in general, since with quinone-hydroquinone pairs that more readily coproportionate and auto-oxidize, twoelectron reduction itself could lead to oxygen activation (17, 25, 44, 45, 49) . The aerobic DQH 2 and DQ-DQH 2 mixtures were quite stable on the time frame relevant to the present studies.
Having made an effort to measure h c (t) and include the capillary transit time dispersion in the modeling, we provide Fig. 14 to give a sense of its impact on the organ function probed in this study. Figure 14 was obtained from model pulse infusion simulations (Eqs. A1-A4) providing simulated effluent concentration data. The simulations were for a lung with the experimentally determined h c (t), a range of k red encompassing the values relevant to this study, and with k o set at constant value of 4.5 ml⅐s Ϫ1 ⅐g dry lung wt
. The curved line is the ratio of the apparent k red that would be estimated if one assumed that there was one common transit time through the lungs to the actual k red used in the simulation. The consequence of ignoring the heterogeneity of the h c (t) would be not only substantial but also dependent on the value of the actual k red value. If one thinks of the lung as a chemical reactor determining the systemic arterial redox status of mixed venous DQ, the simulation also demonstrates how the reactor efficiency can be affected by the heterogeneity of the h c (t) (28) .
In conclusion, this study demonstrates the high capacity of the lungs for reducing DQ as it passes through the pulmonary circulation. The flow-limited tissue access of this amphipathic substrate allows for a simplified expression for the quasisteady-state disposition in terms of the rates of DQ reduction and DQH 2 reoxidation in the intact organ. The reduction appears to be mainly via dicumarol-sensitive two-electron reduction, presumably mediated via NQO1, and the reoxidation mainly via a cyanide-sensitive oxidation, presumably mediated via mitochondrial complex III. The results are consistent with the concept that the net effect of passage through the lungs on this potentially oxygenactivating quinone is a conversion to a stable reduction product. Thus the lungs may have a plasma-detoxifying effect through their capacity for reducing certain classes of plasma-borne redox-active substrates.
APPENDIX

Kinetic Model
Stoichiometry. The free (not plasma protein bound) form of DQ may be reduced to DQH2 via reductase(s) by electron donor(s) EH [e.g., NAD(P)H]. Both DQ and DQH2 may participate in nonspecific, rapidly equilibrating interactions with the perfusate albumin (P c) and the lung tissue sites of association (Pe). The DQ may also be sequestered [i.e., association with, or binding to, some cellular component(s), which results in removal of the DQ from the perfusate and from participation in the other specified reactions]. Each of these reactions proceeds with a rate constant k i in the forward direction and, if reversible, with a rate constant kϪi in the reverse direction. Each of the stoichiometric equations may potentially represent multiple parallel and/or series processes that are not explicitly specified. For example, intracellular reduction might occur via parallel enzymes contributing to the total quinone reductase activity.
In perfusate (c)
14. The influence of ignoring transit time heterogeneity on the apparent kred. The abscissa is the kred used in the model simulation using the measured rat lung hc(t) and designated "actual kred." The ordinate is the ratio of the apparent kred estimated assuming a common capillary transit time to the actual kred of the distributed transit time simulation. Given that a value of 1.0 would mean that the estimate is correct, the magnitude of the "error" can be appreciated. To construct an organ model from Eqs. A1-A4, the h c(t), obtained as described in Ref. 7 , was represented by a shifted random walk function as previously described (4, 6) using the capillary moments (t v, c 2 , and m c 3 ) obtained from the vascular mean transit time, tv, and the tv/ tv, RDc, and SKWc, estimated from the data in Fig. 9 .
The h n(t), which accounts for the system dispersion outside of the capillaries (i.e., in arteries, veins, connecting tubing, and the injection system), is related to h c(t) and the concentration vs. time outflow curve of the vascular indicator, CR(t), by CR(t) ϭ (q2/F) hc(t) * hn(t), where * is the convolution operator, and q2 is the mass of the injected vascular indicator. For the bolus injection, hn(t) was also represented by a shifted random walk function (8) , whereas for the pulse infusion h n(t) was represented by: hn(t) ϭ 0 for 0 Յ t Յ tsp, hn(t) ϭ (1/tp)[1 Ϫ e{Ϫ␥(t Ϫ tsp)]} for tsp Ͻ t Յ tsp ϩ tp, and hn(t) ϭ (1/tp)[e{Ϫ␥(t Ϫ tsp Ϫ tp)} Ϫ e{Ϫ␥(t Ϫ tsp)}] for tsp ϩ tp Ͻ t Ͻ ϱ, where tsp and tp are the pulse time shift and pulse duration, respectively. The parameters of hn(t) (random walk function parameters for bolus injection, and tsp and ␥ for pulse infusion) were specified by iteratively convolving C in(t) ϭ (q2/F)hn(t) with hc(t) until the optimal least squares fit to CR(t) was obtained.
To model DQ bolus injections or pulse infusions, given hc(t) and hn(t), we solved Eqs. A1-A4 numerically (8) . To provide the whole organ output for vascular reference indicator and for DQ and DQH 2, the outputs for all transit times were summed, each weighted according to hc(t). The optimization for fitting the model to the data and parameter estimation was carried out using the IMSL subroutine DB-CLSF (IMSL math/Library, version 2.0, 1994), which finds the best nonlinear least-squares solution using a modified Levenberg-Marquardt algorithm with finite difference Jacobian.
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